INTRODUCTION
============

Inflammatory bowel disease (IBD), including CD and UC, are common chronic GI diseases in Western countries \[[@b1-ir-2018-00096]-[@b4-ir-2018-00096]\]. IBD has been increasing in both incidence and prevalence in many newly industrialized countries since the beginning of the 21st century \[[@b1-ir-2018-00096],[@b3-ir-2018-00096],[@b5-ir-2018-00096]-[@b8-ir-2018-00096]\]. The reason for the global increase in this initially Western-prevalent disease has not been established but is most likely related to environment factors, including improved hygiene, civilization, and the spread of Western lifestyles and diets \[[@b1-ir-2018-00096]\].

Longitudinal studies of Western populations performed within the past 50 years have revealed a pattern of initial increases in UC incidence, followed by increases in CD incidence at various intervals over the specified decades \[[@b3-ir-2018-00096],[@b9-ir-2018-00096]\]. For example, a study in Denmark \[[@b10-ir-2018-00096]\] reported a steady increase in CD incidence but stable UC incidence from 1981 to 1992. In Japan, which was one of the first among Eastern countries to adopt aspects of Western lifestyles, researchers reported a rapid rise of the incidence rate of UC beginning in 1970, with a peak in in 1974, followed by a peak in the CD incidence rate in 1979 \[[@b11-ir-2018-00096]\]. This trend was also observed in other low-incidence Asian countries such as Hong Kong (from 8.94 in 1981--1985 to 1.03 in 2011--2014) \[[@b12-ir-2018-00096]\], South Korea (from 6.8 in 1986--1990 to 2.3 in 2001--2005) \[[@b13-ir-2018-00096]\], and Malaysia (from 8:1 in 1990--2000 to 3.6:1 in 2000--2010) \[[@b14-ir-2018-00096]\].

Western studies have reported that CD and UC are more prevalent among female patients or that no intersex difference exists \[[@b15-ir-2018-00096]\]. By contrast, the data from our study as well as reports from other Asian countries have indicated that IBDs, especially CD, are more prevalent among male patients \[[@b5-ir-2018-00096]\]. Although the exact reason for these disparate patterns is unknown, a difference in genetic background between Asian and Western populations \[[@b16-ir-2018-00096]\] may be a contributing factor, and the male-preference culture in Asian countries may lead to differences for male and female babies regarding breastfeeding, antibiotic use in childhood, and subsequent development of IBDs \[[@b17-ir-2018-00096]\].

In Taiwan, the first case of IBD was diagnosed in 1969 as UC at the National Taiwan University Hospital \[[@b18-ir-2018-00096]\]; however, no reliable nationwide descriptive epidemiology data \[[@b19-ir-2018-00096]\] from the 20 century regarding IBD in Taiwan is available \[[@b5-ir-2018-00096]\]. Since 1997, IBDs, including CD and UC, have been registered as catastrophic illnesses due to their potential to cause repeated admissions and their requirements for chronic, sensitive care. Accordingly, medical costs are covered by insurance for patients registered with relevant diagnoses. Submission of a clinical diagnosis, pathological report, and possibly endoscopic or radiologic image studies for formal review by experts is required to validate and register the patient's diagnosis of CD or UC. In our previous study, we demonstrated that CD and UC increased in both incidence and prevalence in Taiwan from 1998 to 2008, according to the nationwide insurance registration data \[[@b5-ir-2018-00096],[@b8-ir-2018-00096]\]. In this study, we used the same nationwide database and now provide an updated report on the incidence, prevalence, and epidemiological trend of IBD in Taiwanese patients since the beginning of the 21st century.

METHODS
=======

1. Data Source and Ethical Considerations
-----------------------------------------

Data from January 2001 to December 2015 were compiled for this nationwide population-based study of IBD. The National Health Insurance (NHI) is a compulsory program with coverage rate of 99.7% of the population in Taiwan. The NHI claims data provide clinical information including prescription, diagnoses, and hospitalizations for population-based epidemiologic research (<https://dep.mohw.gov.tw/DOS>). Under strict confidentiality guidelines and in accordance with personal electronic data protection regulations, the study population were obtained from NHI data (including Catastrophic Illness Patients Registry and Taiwan Cancer Registry), department of statistics of the Ministry of Health and Welfare, Taiwan. The present study was approved by the Ethics Review Board of the National Taiwan University Hospital (IRB No. 201507018W) and informed consent was waived.

2. Patient Identification
-------------------------

The Ministry of Health and Welfare has classified UC and CD as catastrophic illnesses that require life-long treatment. Patients with a diagnosis of UC or CD generally submit relevant information (including their clinical information, imaging studies, endoscopic studies, and pathology reports) to the NHI program when applying for a catastrophic-illness certificate. After receiving the clinical information, the reviewers of the NHI approve the certification when the diagnosis meets the IBD diagnostic criteria \[[@b20-ir-2018-00096],[@b21-ir-2018-00096]\]. We used diagnostic codes (International Classification of Diseases, Ninth Revision, Clinical Modification 2001 edition) to retrieve the data of patients with IBDs (UC, 556.XX; CD, 555.XX) from the catastrophic-illnessregistration database. As described, the NHI claim database collects the medical records and information of each registered patient, including sex, date of birth, and date of catastrophic-illness registration.

3. Statistical Analyses
-----------------------

The characteristics of the studied group of patients with IBD, including year of registration, sex ratio, and age distribution, are described in this paper. Annual crude incidence and prevalence were defined as the number of newly diagnosed patients and number of patients with IBD per 100,000 persons per year, respectively. All statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA). A P-value of less than 0.05 indicated statistical significance.

RESULTS
=======

1. Incidence and Prevalence of IBD Increased Steadily from 2001 to 2015
-----------------------------------------------------------------------

A total of 3,806 patients with IBD were registered from 2001 to 2015 in Taiwan. Among them, 919 were diagnosed with CD and 2,887 with UC ([Table 1](#t1-ir-2018-00096){ref-type="table"}). As illustrated in [Fig. 1](#f1-ir-2018-00096){ref-type="fig"}, the crude incidence of CD increased from 0.17/100,000 in 2001 to 0.47/100,000 in 2015. The crude incidence of UC increased from 0.54/100,000 in 2001 to 0.95/100,000 in 2015. The joinpoint trend analysis for the general trends in patients diagnosed with IBD were significant from 2001 to 2015, with the annual percent change (APC) as 2.69. The trend of CD also increased significantly according to the joinpoint trend analysis from 2001 to 2015, with the APCs as 4.75 (2001--2010) and 15.92 (2010--2015); whereas they were insignificant of the trend for UC, since the APC value was 0.82 from 2001 to 2015. The crude prevalence of CD increased from 0.6/100,000 in 2001 to 3.9/100,000 in 2015. The crude prevalence of UC increased from 2.1/100,000 in 2001 to 12.8/100,000 in 2015 ([Fig. 2](#f2-ir-2018-00096){ref-type="fig"}).

The study period was arbitrarily divided into the 3 stages: 2001 to 2005; 2006 to 2010; and 2011 to 2015 ([Table 2](#t2-ir-2018-00096){ref-type="table"}) for newly registered IBD. The overall incidence and prevalence of IBD significantly increased over the 3 stages. Additionally, both the incidence of CD (0.18/100,000, 0.22/100,000, and 0.39/100,000; *P*\<0.0001) and prevalence of CD (0.84/100,000, 1.71/100,000, and 3.04/100,000; *P*\<0.0001) increased significantly over the 3 stages ([Table 3](#t3-ir-2018-00096){ref-type="table"}). Finally, although the difference was less significant, the incidence of UC (0.79/100,000, 0.94/100,000, and 0.79/100,000; *P*\<0.0001) and prevalence of UC (3.70/100,000, 7.68/100,000, and 11.36/100,000; *P*\<0.0001) also increased significantly over the 3 stages ([Table 4](#t4-ir-2018-00096){ref-type="table"}).

To clarify the possible factors that contributed to this change, we grouped the patients with CD according to age, and we then discovered that the increase in CD was mostly concentrated in individuals aged 20 to 39 years ([Fig. 3](#f3-ir-2018-00096){ref-type="fig"}).

2. UC-to-CD Incidence Ratio Decreased from 2001 to 2015 in Taiwan
-----------------------------------------------------------------

We then compared the incidence ratio of UC to CD ([Fig. 4](#f4-ir-2018-00096){ref-type="fig"}) from 2001 to 2015 and determined that it significantly decreased from 4.32 to 4.17 and finally to 2.03 across the 3 stages.

3. Sex and Age Distribution Trends
----------------------------------

A male-predominant pattern for IBD in Taiwan, and more so for CD than for UC, was evident across all 3 stages. The overall male-to-female ratio was 2.19 for CD and 1.62 for UC. The male-to-female ratios of CD and UC were steady over the 3 stages from 2001 to 2015 ([Fig. 5](#f5-ir-2018-00096){ref-type="fig"}).

The mean ages of registration for IBD, CD, and UC from 2001 to 2015 were 43.29, 37.95, and 44.94 years, respectively. No significant change was evident regarding the median ages of patients at registration for IBD, CD, and UC over the 3 stages. To identify which subpopulations exhibited the most significant increases in CD and UC registrations during the study period, we compared the incidence of CD and UC in 4 age groups ( ≤ 19, 20--39, 40--59, and ≥ 60 years) from 2001 to 2015. We identified a significantly greater increase in the incidence rate among the 20 to 39 years group (*P*\<0.0001) compared with the other age groups ([Fig. 6](#f6-ir-2018-00096){ref-type="fig"}).

DISCUSSION
==========

Analyzing data from the nationwide insurance registration system, we demonstrated that the incidence and prevalence of IBD increased steadily from 2001 to 2015 in Taiwan. Globally, the incidence level of IBD is highest in Western countries, with annual rates as high as 24.3 people per 100,000 for UC and 29.3 people per 100,000 for CD \[[@b1-ir-2018-00096],[@b2-ir-2018-00096],[@b7-ir-2018-00096]\]. The present study revealed that the incidence rates of UC (0.95/100,000) and CD (0.47/100,000) have been increasing in Taiwan since the beginning of the 21st century. The incidence rates in Taiwan are low compared with those in Japan, South Korea \[[@b19-ir-2018-00096]\], and Hong Kong \[[@b7-ir-2018-00096],[@b12-ir-2018-00096]\] but are similar to those in other Asian countries such as Singapore, Malaysia, and Thailand \[[@b1-ir-2018-00096]\]. Differences in degree of urbanization and socioeconomic status among the populations of these regions may have contributed to the described variation \[[@b5-ir-2018-00096]\]. In the present study, incidence levels may have been underestimated, because we used relatively stringent criteria for analysis. In studies of other countries, most incidence and prevalence levels have been calculated using clinical-diagnosis data only. By contrast, incidence and prevalence levels in this study were based on numbers of patients who had completed catastrophic-illness registration, which requires clinical records, endoscopic images, and pathology results.

In this study, we first demonstrated a decrease in the UC-to-CD incidence ratio in Taiwan. Decreases have also been observed in other low-incidence Asian countries such as Hong Kong (from 8.94 in 1981--1985 to 1.03 in 2011--2014) \[[@b12-ir-2018-00096]\], South Korea (from 6.8 in 1986--1990 to 2.3 in 2001--2005) \[[@b13-ir-2018-00096]\], and Malaysia (from 8:1 in 1990--2000 to 3.6:1 in 2000--2010) \[[@b14-ir-2018-00096]\]. By contrast, the UC-to-CD ratio has remained steady in Western countries ([Fig. 7](#f7-ir-2018-00096){ref-type="fig"}) \[[@b9-ir-2018-00096],[@b12-ir-2018-00096],[@b13-ir-2018-00096],[@b19-ir-2018-00096],[@b22-ir-2018-00096]-[@b24-ir-2018-00096]\]. Consistent with other studies from developing countries, we demonstrated that UC remains the predominant IBD in Asia and is twice as common as CD. Historically, the incidence of UC has usually increased first, followed by that of CD \[[@b2-ir-2018-00096]\]. For instance, a study conducted in Denmark \[[@b10-ir-2018-00096]\] revealed a steady increase in CD incidence alongside a stable UC incidence from 1981 to 1992. In Japan, the incidence rate of UC peaked in 1974 whereas that of CD peaked in 1979 \[[@b11-ir-2018-00096]\]. A similar trend was observed in the present study: in Taiwan, UC-to-CD ratio significantly decreased during the study period, from 4.32 (2001--2005) to 4.17 (2006--2010) to 2.03 (2011--2015).

The reason for the catch-up of CD incidence between Taiwan and countries with higher incidence levels is not clear, but the trend may reflect common risk factors for CD and UC among various populations, such as improved social economic status and diet. The time lag between increases in UC and CD incidences may imply that the pathogeneses of the diseases differ \[[@b12-ir-2018-00096]\] or may reflect improvements in CD-diagnosis accuracy \[[@b9-ir-2018-00096]\]. The diagnosis of UC is usually straightforward and based on endoscopic findings from sigmoidoscopy \[[@b20-ir-2018-00096]\]. By contrast, the diagnosis of CD is more complex and sometimes requires multiple evaluations, including enteroscopic, pathologic, and radiologic evaluations \[[@b21-ir-2018-00096]\]. We speculate that the improved endoscopic technology of the 21st century---that is, capsule endoscopy and deep enteroscopy \[[@b25-ir-2018-00096]\]---may have enabled earlier diagnosis of CD. This phenomenon may partially explain the relatively steep increases in the CD incidence rate in most Asian countries in the 21st century \[[@b26-ir-2018-00096]\].

In the present study, the most common age of registration of patients with CD was between 20 and 39 years, whereas that for UC was between 40 and 59 years. The mean age of patients registered with CD and UC was compared with that from reports conducted in other countries in Asia \[[@b20-ir-2018-00096],[@b21-ir-2018-00096]\]. Although the results of the present study revealed that the median age of patient IBD registration did not significantly change during 2001 to 2015, a significant increase in the CD incidence rate was discovered among 20 to 39-year-old. Additionally, we found that the previously identified male predominance continued, with the male-to-female ratio not changing from 2001 to 2015.

Our findings may have several implications for medical practice in Taiwan as well as in other Asian countries with low IBD incidence. First, similar to the increased incidence of IBD, an increased incidence of colorectal cancer has been observed in Taiwan, and the need for colonoscopy screening has increased \[[@b27-ir-2018-00096]\]. Thus, endoscopists must learn to diagnose colorectal neoplasm and IBD early to improve patient outcomes. Specifically, endoscopists with experience in IBD care must diagnose IBD early, differentiate among instances of IBD and infectious colitis, and help patients manage IBD-related complications. The Taiwan Society of Inflammatory Bowel Disease (TSIBD) was founded in 2013 with the aim of improving awareness, quality of care, and outcomes for patients with IBD in Taiwan \[[@b20-ir-2018-00096],[@b21-ir-2018-00096]\]. Second, the high cost of caring for patients with IBD combined with the increased incidence of IBD may have a considerable financial effect on the health care system \[[@b28-ir-2018-00096]\]. The use of biologic therapy has been suggested to reduce requirements for surgery and hospitalization and to improve quality of life and work productivity among patients with IBD \[[@b29-ir-2018-00096],[@b30-ir-2018-00096]\]. However, the Taiwan health insurance criteria for biologic-therapy coverage and coverage period are more stringent than those for most other countries discussed herein, such as Japan and South Korea \[[@b30-ir-2018-00096]\]. Therefore, the TSIBD multicenter IBD registry study \[[@b31-ir-2018-00096]\] was initiated to obtain precise data on IBD patient clinical information, disease phenotype, and treatment strategies and outcomes. These data may eventually prompt the health care system to cover more expenses for patients with TBD.

Some of the factors associated with IBD incidence may also be associated with changes in disease severity over time. For example, IBD in Western countries may still be more severe than in Asia. Analyzing the incidence trend of IBD may provide clues regarding IBD pathogenesis \[[@b3-ir-2018-00096]\]. Policy planners and taxpayers should understand the global burden of IBD. Proof that IBD has a considerable disease burden may affect research funding allocated by national authorities.

This study has some intrinsic limitations from registration data. First, it is possible that a portion of IBD patients were not registered with catastrophic illness and not included in the current study. Second, our catastrophic illnesses registration permitted either UC or CD but not IBD-unclassified. Third, there was also no detail data regarding the disease location, activity, patterns of drugs used for patients included in this study. Fourth, there is no firm diagnostic criteria of UC and CD in Taiwan. The NHI reviewer usually give certification of IBD with reference to the Taiwan consensus for UC \[[@b20-ir-2018-00096]\] and CD \[[@b21-ir-2018-00096]\].

In conclusion, using Taiwan's nationwide insurance database to identify patients with IBD, the present study revealed that the incidence and prevalence of IBD in Taiwan steadily increased from 2001 to 2015. The number of patients with CD increased more rapidly than that of patients with UC. Although the incidence of IBD remains low in Taiwan, the upward trend in CD incidence in Taiwan as well as other developed countries suggests that requirements for IBD care will be greater in the future.
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###### 

The Incidence Rate of IBD, CD, and UC from 2001 to 2015

  Year    Population   IBD     CD           UC             
  ------- ------------ ------- ------ ----- ------ ------- ------
  2001    22,341,120   160     0.72   39    0.17   121     0.54
  2002    22,463,172   220     0.98   32    0.14   188     0.84
  2003    22,562,663   233     1.03   41    0.18   192     0.85
  2004    22,646,836   215     0.95   48    0.21   167     0.74
  2005    22,729,753   263     1.16   45    0.20   218     0.96
  2006    22,823,455   243     1.06   46    0.20   197     0.86
  2007    22,917,444   231     1.01   43    0.19   188     0.82
  2008    22,997,696   266     1.16   51    0.22   215     0.93
  2009    23,078,402   296     1.28   61    0.26   235     1.02
  2010    23,140,948   299     1.29   57    0.25   242     1.05
  2011    23,193,518   205     0.88   55    0.24   150     0.65
  2012    23,270,367   256     1.10   86    0.37   170     0.73
  2013    23,344,670   278     1.19   86    0.37   192     0.82
  2014    23,403,635   307     1.31   118   0.50   189     0.81
  2015    23,462,914   334     1.42   111   0.47   223     0.95
  Total                3,806          919          2,887   

IR, incidence rate.

###### 

Clinical Features of Patients with Newly Registered IBD in 2001 to 2015

  All IBD                  Over all        Stage 1 (2001--2005)   Stage 2 (2006--2010)   Stage 3 (2011--2015)   *P*-value
  ------------------------ --------------- ---------------------- ---------------------- ---------------------- -----------
  No. of cases (UC/CD)     2,887/919       886/205                835/201                1,166/513              \-
  Age (yr)                                                                                                      
   Mean                    43.29±16.58     43.98±17.00            43.46±16.22            42.74±16.62            0.1478
   Median (Q1--Q3)         42 (31--54)     43 (32--55)            42 (32--54)            43 (30--55)            
   Age distribution                                                                                             0.5689
    \<20                   243 (6.38)      67 (6.14)              58 (5.60)              118 (7.03)             
    20--39                 1,418 (37.26)   387 (35.47)            406 (39.19)            625 (37.22)            
    40--59                 1,492 (39.2)    434 (39.78)            406 (39.19)            652 (38.83)            
    60--79                 592 (15.55)     185 (16.96)            149 (14.38)            258 (15.37)            
    ≥80                    61 (1.60)       18 (1.65)              17 (1.64)              26 (1.55)              
  Male/female ratio        1.74            1.73                   1.59                   1.86                   0.1663
  Prevalence (1/100,000)   9.50            4.54                   9.39                   14.40                  \<0.0001
  Incidence (1/100,000)    1.11            0.97                   1.16                   1.18                   \<0.0001

Values are presented as mean±SD, median (range), or number (%).

###### 

Clinical Features of Patients with CD in 2001 to 2015

  CD                         Over all      Stage 1 (2001--2005)   Stage 2 (2006--2010)   Stage 3 (2011--2015)   *P*-value
  -------------------------- ------------- ---------------------- ---------------------- ---------------------- -----------
  No. of cases               919           205                    201                    513                    \-
  Age (yr)                                                                                                      
   Mean                      37.95±18.41   37.83±19.94            38.52±18.34            38.03±17.93            0.9249
   Median (Q1--Q3)           35 (24--50)   37 (23--51)            36 (25--50)            34 (25--50)            
   Peak age (top 5 age, %)                                                                                      
                             25 (2.99)     0 (4.39)               25 (4.48)              30 (3.70)              
                             32 (2.89)     39 (3.90)              23 (3.98)              29 (3.12)              
                             29 (2.69)     20 (3.41)              18 (3.48)              27 (2.92)              
                             22 (2.59)     22 (3.41)              26 (3.48)              25 (2.73)              
                             30 (2.49)     37 (2.93)              33 (2.99)              31 (2.73)              
   Age groups                                                                                                   0.7740
    \<20                     128 (13.93)   34 (16.59)             27 (13.43)             67 (13.06)             
    20--39                   415 (45.16)   81 (39.51)             92 (45.77)             242 (47.17)            
    40--59                   241 (26.22)   61 (29.76)             53 (26.37)             127 (24.76)            
    60--79                   115 (12.51)   25 (12.20)             25 (12.44)             65 (12.67)             
    ≥80                      20 (2.18)     4 (1.95)               4 (1.99)               12 (2.34)              
  Male/female ratio          2.19          2.25                   2.72                   2.00                   0.2402
  Prevalence (1/100,000)     1.88          0.84                   1.71                   3.04                   \<0.0001
  Incidence (1/100,000)      0.27          0.18                   0.22                   0.39                   \<0.0001

Values are presented as mean±SD, median (range), or number (%).

###### 

Clinical Features of Patients with UC in 2001 to 2015

  UC                         Over all        Stage 1 (2001--2005)   Stage 2 (2006--2010)   Stage 3 (2011--2015)   *P*-value
  -------------------------- --------------- ---------------------- ---------------------- ---------------------- -----------
  No. of cases               2,887           886                    835                    1,166                  \-
  Age (yr)                                                                                                        
   Mean                      44.94±15.61     45.41±15.92            44.65±15.44            44.82±15.58            0.5654
   Median (Q1--Q3)           44 (34--55)     44 (34--56)            43 (34--55)            45 (33--56)            
   Peak age (top 5 age, %)                                                                                        
                             38 (2.99)       34 (3.05)              38 (3.47)              49 (3.00)              
                             43 (2.74)       38 (3.05)              37 (3.11)              47 (2.92)              
                             49 (2.71)       40 (2.93)              49 (3.11)              43 (2.74)              
                             42 (2.68)       43 (2.93)              39 (2.99)              32 (2.49)              
                             47 (2.62)       42 (2.82)              42 (2.99)              41 (2.49)              
   Age groups                                                                                                     0.3793
    \<20                     115 (3.98)      33 (3.72)              31 (3.71)              51 (4.37)              
    20--39                   1,003 (34.74)   306 (34.54)            314 (37.60)            383 (32.85)            
    40--59                   1,251 (43.33)   373 (42.10)            353 (42.28)            525 (45.03)            
    60--79                   477 (16.52)     160 (18.06)            124 (14.85)            193 (16.55)            
    ≥80                      41 (1.42)       14 (1.58)              13 (1.56)              14 (1.20)              
  Male/female ratio          1.62            1.63                   1.41                   1.80                   0.0361
  Prevalence (1/100,000)     7.62            3.70                   7.68                   11.36                  \<0.0001
  Incidence (1/100,000)      0.84            0.79                   0.94                   0.79                   \<0.0001

Values are presented as mean±SD, median (range), or number (%).
